Biocartis

18/08/2025

📣 Molecular biomarker results in only 3 hours! THINK IDYLLA™

But what does ‘molecular’ actually mean?... 🤔

💡 ‘Molecular diagnostics’ or ‘molecular pathology’ involves analyzing molecules (such as DNA, RNA and proteins) from a tissue or liquid sample for presence of biological markers that can pinpoint the potential (re-)emergence of a specific disease, such as cancer, and aid in planning and monitoring the patient’s treatment.

👉 Idylla™ makes molecular diagnostics convenient, fast and suitable for any lab: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1808_meet-idylla

14/08/2025

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗖𝗣𝟮𝟬𝟮𝟱? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁!
📍 Booth 52 | 🗓️ 6 - 10 September |🗺️ Vienna, Austria

Stop by 𝗯𝗼𝗼𝘁𝗵 𝟱𝟮 to discover how Idylla™ can deliver your 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀! ⏱️
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 and get a live demo: https://www.biocartis.com/en/press-events/events

🎤 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗵𝗼𝘁𝘀𝗽𝗼𝘁 𝘀𝗲𝘀𝘀𝗶𝗼𝗻!
On Tuesday 𝟵 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿, 𝟭𝟬:𝟬𝟬 𝗔𝗠 (CEST), Caroline Jans will be presenting the new 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 at the Hostpot Stage (Hall X5). This Assay is designed for the fast and straightforward detection of POLE and POLD1 mutations - key biomarkers associated with the hypermutated phenotype in endometrial cancer.
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗔𝘀𝘀𝗮𝘆 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗶𝗺𝗲: https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay

See you there? 👋

𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘖𝘓𝘌-𝘗𝘖𝘓𝘋1 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 𝘪𝘴 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.

12/08/2025

☀️Enjoy your summer vacation while your fully automated Idylla™ Platform keeps running your molecular biomarker tests!
Discover Idylla™ 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1208_meet-idylla

11/08/2025

📣 At Biocartis, we aspire to make personalized medicine available to patients around the world!

But what does ‘personalized medicine’ actually mean?... 🤔

💡 ‘Personalized medicine’ or ‘precision medicine’ tailors medical decisions (e.g., treatment) to a specific patient based on their genetic and genomic data (e.g., biomarker).

💡 In cancer, assessing and quantifying the presence of a biomarker associated with a patient’s tumor can provide crucial information on whether a patient is eligible for more effective targeted treatment.

Biomarker testing with Idylla™ makes molecular testing actionable, convenient, fast & suitable for any lab, and consequently contributes to giving patients access to personalized medicine!
👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1108_meet-idylla

08/08/2025

Molecular biomarker results in ONLY 3 HOURS 🔬
💡 THINK IDYLLA™

Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

More information 👉 https://www.biocartis.com/en/meet-idylla

06/08/2025

📢 Discover the 𝗻𝗲𝘄𝗹𝘆 𝗜𝗩𝗗𝗥-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗘𝗚𝗙𝗥 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗧𝗲𝘀𝘁*!
𝗪𝗵𝗮𝘁 𝘀𝗲𝘁𝘀 𝗼𝘂𝗿 𝗧𝗲𝘀𝘁 𝗮𝗽𝗮𝗿𝘁?
✔️ 44 EGFR mutation detection across exons 18-21
✔️ CDx for EGFR exon 19 deletions and L858R
✔️ 99.2% sensitivity, 99.0% specificity for CDx targets
✔️ Fully automated results in ~150 minutes
✔️ < 3 min hands-on time
✔️ IVDR-compliant = meets Europe’s stringent new regulatory standards

👉 Learn more: https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-egfr-mutation-test
*CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR)

04/08/2025

Why is fast biomarker testing important in LUNG CANCER? 🤔

🧬BIOMARKER TESTING?
By analyzing tumor tissue or blood samples, doctors can learn the details of a patient’s specific tumor. If certain biomarkers are identified, cancer therapy can be personalized for each patient which often means more effective therapies.

🏎️ FAST?
Patients often receive sub-optimal treatment, rapidly deteriorate or even die while waiting for their biomarker test results(1-3). Patients should be given the most effective treatment first time around, since this not only alleviates patient anxiety(4-5), but also impacts their overall rate of survival(6).

👉 Biomarker results in only 3 hours for fast treatment decisions! THINK IDYLLA™ https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0408_meet-idylla



Sources: https://www.biocartis.com/en/references-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0408_meet-idylla

02/08/2025

🌍 𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 𝐖𝐨𝐫𝐥𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐃𝐚𝐲 — a moment to celebrate breakthroughs that are reshaping how we detect, diagnose, and treat disease.

At Biocartis, innovation means making personalized medicine more accessible to cancer patients worldwide through universal access to molecular testing.
The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 simplifies complex molecular testing by delivering fast & accurate biomarker results in only 3 hours, with < 3 minutes hands-on time.

🔬 Learn more about how Idylla™ is driving innovation in molecular diagnostics: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0208_meet-idylla

01/08/2025

📅 Today is 𝐖𝐨𝐫𝐥𝐝 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲

Although lung cancer remains the leading cause of cancer deaths worldwide, the survival rate has increased over the past few years due to the rapidly evolving treatment landscape for Non-Small Cell Lung Cancer (NSCLC).
As therapies become more biomarker-driven, the need for fast, accurate biomarker testing is critical.
💡𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐨𝐧𝐥𝐲 𝟑 𝐡𝐨𝐮𝐫𝐬!
https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=cpc&utm_campaign=0108_idylla-for-lung-cancer

𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫, 𝐰𝐞 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐠𝐞𝐭 𝐟𝐚𝐬𝐭, 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 💪

Idylla™ delivers molecular biomarker results in only 3 hours!

30/07/2025

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf


*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

29/07/2025

🔬 We're live at the Association for Academic Pathology 2025 Annual Meeting in Denver, CO, US (July 27–30)!

Curious how you can get 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀? ⏱️
Come see 𝗜𝗱𝘆𝗹𝗹𝗮™ in action and discover how we're streamlining pathology workflows 👉 https://www.biocartis.com/en-US/meet-idylla

𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 🤝 https://www.biocartis.com/en-US/news-events/events/aapath

28/07/2025

Do you know the difference between NSCLC and SCLC? 🤔

👉 NSCLC = non-small cell lung cancer
- Cells are large 🔬
- Common
- Often develops slowly
- Typically identified at a later stage

👉 SCLC = small cell lung cancer
- Cells are small and round 🔬
- Less common
- More aggressive
- Spreads quickly and to other parts of your body

👀 Discover the Biocartis NSCLC Portfolio: https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=2807_idylla-for-lung-cancer